Study Details

Back
Study ID 2215-CL-0102
Study Title A Phase 1 Open-label, Dose-escalation Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
Clinicaltrials.gov Identifier NCT02181660
Compound Name ASP2215 / gilteritinib fumarate
Medical Indication or Disease Acute myeloid leukemia
Study Sponsor Astellas Pharma Inc.
Collaborator Not Applicable
Study Start Date 16-Jun-2014
Study Completion Date 27-Jun-2016
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
Japanese

QUICK SEARCH

USEFUL LINKS